Pfizer withdrew Oxbryta (voxelotor), a conditionally approved oral therapy for SCD, saying its benefits don't outweigh risks.

A Nigerian hematologist will pursue a PhD in health policy at the University of Tennessee Health Science Center to help advance her work on programs for sickle cell disease (SCD) in her home country.

Infections in sickle cell disease can be problematic and even fatal. Columnist Oluwatosin Adesoye, a patient and doctor, has ...

The women's sorority plans to donate $2 million by 2028 to St. Jude Children's Research Hospital, which offers care at no ...

Sickle cell carriers are at a slightly increased risk of blood clots, but the overall risk is still low, a study found.

In honor of September's Sickle Cell Awareness Month, columnist Oluwatosin Adesoye shares her reasons for advocating for ...

One sickle cell disease (SCD) patient may need as many as 50 units of blood and up to 25 units of platelets for the new cell-based gene therapies such as Casgevy and Lyfgenia to be successfully ...